429 related articles for article (PubMed ID: 22419746)
1. Circulating luteinizing hormone level after triggering oocyte maturation with GnRH agonist may predict oocyte yield in flexible GnRH antagonist protocol.
Chen SL; Ye DS; Chen X; Yang XH; Zheng HY; Tang Y; He YX; Guo W
Hum Reprod; 2012 May; 27(5):1351-6. PubMed ID: 22419746
[TBL] [Abstract][Full Text] [Related]
2. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
[TBL] [Abstract][Full Text] [Related]
3. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
[TBL] [Abstract][Full Text] [Related]
4. The use of gonadotropin-releasing hormone (GnRH) agonist to induce oocyte maturation after cotreatment with GnRH antagonist in high-risk patients undergoing in vitro fertilization prevents the risk of ovarian hyperstimulation syndrome: a prospective randomized controlled study.
Engmann L; DiLuigi A; Schmidt D; Nulsen J; Maier D; Benadiva C
Fertil Steril; 2008 Jan; 89(1):84-91. PubMed ID: 17462639
[TBL] [Abstract][Full Text] [Related]
5. GnRH agonist (buserelin) or hCG for ovulation induction in GnRH antagonist IVF/ICSI cycles: a prospective randomized study.
Humaidan P; Bredkjaer HE; Bungum L; Bungum M; Grøndahl ML; Westergaard L; Andersen CY
Hum Reprod; 2005 May; 20(5):1213-20. PubMed ID: 15760966
[TBL] [Abstract][Full Text] [Related]
6. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
[TBL] [Abstract][Full Text] [Related]
7. Oocyte maturation employing a GnRH agonist in combination with low-dose hCG luteal rescue minimizes the severity of ovarian hyperstimulation syndrome while maintaining excellent pregnancy rates.
Radesic B; Tremellen K
Hum Reprod; 2011 Dec; 26(12):3437-42. PubMed ID: 21997895
[TBL] [Abstract][Full Text] [Related]
8. Predicting suboptimal oocyte yield following GnRH agonist trigger by measuring serum LH at the start of ovarian stimulation.
Popovic-Todorovic B; Santos-Ribeiro S; Drakopoulos P; De Vos M; Racca A; Mackens S; Thorrez Y; Verheyen G; Tournaye H; Quintero L; Blockeel C
Hum Reprod; 2019 Oct; 34(10):2027-2035. PubMed ID: 31560740
[TBL] [Abstract][Full Text] [Related]
9. Gonadotropin-releasing hormone agonist trigger in oocyte donors co-treated with a gonadotropin-releasing hormone antagonist: a dose-finding study.
Vuong TN; Ho MT; Ha TD; Phung HT; Huynh GB; Humaidan P
Fertil Steril; 2016 Feb; 105(2):356-63. PubMed ID: 26523330
[TBL] [Abstract][Full Text] [Related]
10. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis.
Griesinger G; Diedrich K; Devroey P; Kolibianakis EM
Hum Reprod Update; 2006; 12(2):159-68. PubMed ID: 16254001
[TBL] [Abstract][Full Text] [Related]
11. Factors that predict the probability of a successful clinical outcome after induction of oocyte maturation with a gonadotropin-releasing hormone agonist.
Kummer N; Benadiva C; Feinn R; Mann J; Nulsen J; Engmann L
Fertil Steril; 2011 Jul; 96(1):63-8. PubMed ID: 21565337
[TBL] [Abstract][Full Text] [Related]
12. Consistent high clinical pregnancy rates and low ovarian hyperstimulation syndrome rates in high-risk patients after GnRH agonist triggering and modified luteal support: a retrospective multicentre study.
Iliodromiti S; Blockeel C; Tremellen KP; Fleming R; Tournaye H; Humaidan P; Nelson SM
Hum Reprod; 2013 Sep; 28(9):2529-36. PubMed ID: 23873146
[TBL] [Abstract][Full Text] [Related]
13. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
[TBL] [Abstract][Full Text] [Related]
14. Predicting successful induction of oocyte maturation after gonadotropin-releasing hormone agonist (GnRHa) trigger.
Kummer NE; Feinn RS; Griffin DW; Nulsen JC; Benadiva CA; Engmann LL
Hum Reprod; 2013 Jan; 28(1):152-9. PubMed ID: 23077235
[TBL] [Abstract][Full Text] [Related]
15. Assessing the adequacy of gonadotropin-releasing hormone agonist leuprolide to trigger oocyte maturation and management of inadequate response.
Chang FE; Beall SA; Cox JM; Richter KS; DeCherney AH; Levy MJ
Fertil Steril; 2016 Oct; 106(5):1093-1100.e3. PubMed ID: 27341988
[TBL] [Abstract][Full Text] [Related]
16. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
[TBL] [Abstract][Full Text] [Related]
17. GnRH-agonist ovulation trigger in patients undergoing controlled ovarian hyperstimulation for IVF with ultrashort flare GnRH-agonist combined with multidose GnRH-antagonist protocol.
Orvieto R; Nahum R; Zohav E; Liberty G; Anteby EY; Meltcer S
Gynecol Endocrinol; 2013 Jan; 29(1):51-3. PubMed ID: 22857268
[TBL] [Abstract][Full Text] [Related]
18. Dual trigger of oocyte maturation with gonadotropin-releasing hormone agonist and low-dose human chorionic gonadotropin to optimize live birth rates in high responders.
Griffin D; Benadiva C; Kummer N; Budinetz T; Nulsen J; Engmann L
Fertil Steril; 2012 Jun; 97(6):1316-20. PubMed ID: 22480822
[TBL] [Abstract][Full Text] [Related]
19. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
[TBL] [Abstract][Full Text] [Related]
20. Impact of clomiphene citrate during ovarian stimulation on the luteal phase after GnRH agonist trigger.
Derksen L; Tournaye H; Stoop D; Van Vaerenbergh I; Bourgain C; Polyzos NP; Haentjens P; Blockeel C
Reprod Biomed Online; 2014 Mar; 28(3):359-68. PubMed ID: 24456700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]